{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:46:45Z","timestamp":1790754405655,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>PSMA-targeted radioligand therapies (PSMA RLT) are an effective and safe option for metastatic castration-resistant prostate cancer, but responsive subtypes and their biomarkers are not fully defined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Plasma samples for cell-free DNA (cfDNA) analysis were collected from 17 patients undergoing [\u00b9\u2077\u2077Lu]Lu-PSMA-I&amp;T. CfDNA underwent whole-genome sequencing to establish copy number variation (CNV) profiles and circulating-tumor DNA (ctDNA) levels and compared between prostate-specific antigen (PSA) response- and 1-year overall survival (1YOS) groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Non-responders exhibited higher degrees of cfDNA CNV burden (<jats:italic>P<\/jats:italic>\u2009=\u20090.048) and higher ctDNA levels (<jats:italic>P\u2009=<\/jats:italic>\u20090.036) than responders. Both markers allowed for the differentiation of responses (AUC: 0.792, 0.806) and 1YOS (AUC: 0.778, 0.847).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Unresponsive patients exhibited higher levels of cfDNA genomic instability and ctDNA levels, warranting genome-wide CNV profiling studies next to targeted approaches for mechanistic radiobiological insights and their value as response biomarkers for PSMA RLTs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07280-5","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:08:32Z","timestamp":1745302112000},"page":"4151-4156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Genomic instability is associated with response to [\u00b9\u2077\u2077Lu]Lu-PSMA-I&amp;T radioligand therapy: an exploratory, preliminary liquid biopsy analysis"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-7314","authenticated-orcid":false,"given":"Kilian","family":"Kluge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Haberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Kumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4222-4083","authenticated-orcid":false,"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"7280_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7280_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus Cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397.","journal-title":"Lancet Oncol"},{"key":"7280_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325.","journal-title":"Lancet Oncol"},{"key":"7280_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.semnuclmed.2024.02.007","volume":"54","author":"H Ahmadzadehfar","year":"2024","unstructured":"Ahmadzadehfar H, Seifert R, Afshar-Oromieh A, Kratochwil C, Rahbar K. Prostate cancer theranostics with 177Lu-PSMA. Semin Nucl Med. 2024;54:581\u201390.","journal-title":"Semin Nucl Med"},{"key":"7280_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","volume":"57","author":"M Crumbaker","year":"2023","unstructured":"Crumbaker M, Goldstein LD, Murray DH, Tao J, Pathmanandavel S, Boulter N, et al. Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617. Eur Urol Open Sci. 2023;57:30\u20136.","journal-title":"Eur Urol Open Sci"},{"key":"7280_CR6","first-page":"5008","volume":"42","author":"JS De Bono","year":"2024","unstructured":"De Bono JS, Morris MJ, Sartor O, Wei XX, Fizazi K, Herrmann K, et al. Baseline ctdna analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore. J Clin Orthod. 2024;42:5008\u20135008.","journal-title":"J Clin Orthod"},{"key":"7280_CR7","doi-asserted-by":"publisher","first-page":"e2300634","DOI":"10.1200\/PO.23.00634","volume":"8","author":"R Raychaudhuri","year":"2024","unstructured":"Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, et al. Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: A retrospective multicenter cohort study. JCO Precis Oncol. 2024;8:e2300634.","journal-title":"JCO Precis Oncol"},{"key":"7280_CR8","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1158\/1538-7445.AM2023-5614","volume":"83","author":"H Fettke","year":"2023","unstructured":"Fettke H, Kostos L, Buteau J, Steen JA, Medhurst E, Haskali MB, et al. Abstract 5614: genomic aberrations in Circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). Cancer Res. 2023;83:5614\u20135614.","journal-title":"Cancer Res"},{"key":"7280_CR9","doi-asserted-by":"publisher","unstructured":"Sartor O, Ledet E, Huang M, Schwartz J, Lieberman A, Lewis B et al. Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers. J Nucl Med [Internet]. 2023; Available from: https:\/\/doi.org\/10.2967\/jnumed.123.266167","DOI":"10.2967\/jnumed.123.266167"},{"key":"7280_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1200\/JCO.2023.41.6_suppl.243","volume":"41","author":"SM Lanka","year":"2023","unstructured":"Lanka SM, Jang A, Sweeney PL, Gupta K, Caputo S, Casado C, et al. Evaluation of ctdna in patients treated with lutetium-177-PSMA-617. J Clin Oncol. 2023;41:243\u2013243.","journal-title":"J Clin Oncol"},{"key":"7280_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","volume":"53","author":"J Vanwelkenhuyzen","year":"2023","unstructured":"Vanwelkenhuyzen J, Van Bos E, Van Bruwaene S, Lesage K, Maes A, \u00dcstmert S, et al. AR and PI3K genomic profiling of cell-free DNA can identify poor responders to lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer. Eur Urol Open Sci. 2023;53:63\u20136.","journal-title":"Eur Urol Open Sci"},{"key":"7280_CR12","doi-asserted-by":"publisher","unstructured":"Ulz P, Belic J, Graf R, Auer M, Lafer I, Fischereder K et al. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat Commun [Internet]. 2016;7. Available from: https:\/\/doi.org\/10.1038\/ncomms12008","DOI":"10.1038\/ncomms12008"},{"key":"7280_CR13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","volume":"153","author":"SC Baca","year":"2013","unstructured":"Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153:666\u201377.","journal-title":"Cell"},{"key":"7280_CR14","doi-asserted-by":"publisher","first-page":"11139","DOI":"10.1073\/pnas.1411446111","volume":"111","author":"H Hieronymus","year":"2014","unstructured":"Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A. 2014;111:11139\u201344.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7280_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.05.030","volume":"80","author":"S Sumanasuriya","year":"2021","unstructured":"Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, et al. Elucidating prostate Cancer behaviour during treatment via Low-pass Whole-genome sequencing of Circulating tumour DNA. Eur Urol. 2021;80:243\u201353.","journal-title":"Eur Urol"},{"key":"7280_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/clinchem\/hvac224","volume":"69","author":"M N\u00f8rgaard","year":"2023","unstructured":"N\u00f8rgaard M, Bjerre MT, Freds\u00f8e J, Vang S, Jensen JB, De Laere B, et al. Prognostic value of Low-Pass whole genome sequencing of Circulating tumor DNA in metastatic Castration-Resistant prostate Cancer. Clin Chem. 2023;69:386\u201398.","journal-title":"Clin Chem"},{"key":"7280_CR17","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00259-024-06698-7","volume":"51","author":"K Kluge","year":"2024","unstructured":"Kluge K, Einspieler H, Haberl D, Spielvogel C, Amereller D, Egger G, et al. Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET\/CT and Circulating tumor DNA in prostate cancer-a cross-sectional study. Eur J Nucl Med Mol Imaging. 2024;51:2833\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7280_CR18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324.","journal-title":"Nat Commun"},{"key":"7280_CR19","doi-asserted-by":"publisher","unstructured":"Mitchell T, Neal DE. The genomic evolution of human prostate cancer [Internet]. British Journal of Cancer. Nature Publishing Group; 2015. pp. 193\u20138. Available from: https:\/\/doi.org\/10.1038\/bjc.2015.234","DOI":"10.1038\/bjc.2015.234"},{"key":"7280_CR20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bj.2021.02.003","volume":"44","author":"O P\u00f6s","year":"2021","unstructured":"P\u00f6s O, Radvanszky J, Bugly\u00f3 G, P\u00f6s Z, Rusnakova D, Nagy B, et al. DNA copy number variation: main characteristics, evolutionary significance, and pathological aspects. Biomed J. 2021;44:548\u201359.","journal-title":"Biomed J"},{"key":"7280_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrg2593","volume":"10","author":"PJ Hastings","year":"2009","unstructured":"Hastings PJ, Lupski JR, Rosenberg SM, Ira G. Mechanisms of change in gene copy number. Nat Rev Genet. 2009;10:551\u201364.","journal-title":"Nat Rev Genet"},{"key":"7280_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.119.234559","volume":"61","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, et al. Patients resistant against PSMA-targeting \u03b1-radiation therapy often harbor mutations in DNA damage-repair-associated genes. J Nucl Med. 2020;61:683\u20138.","journal-title":"J Nucl Med"},{"key":"7280_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12943-022-01551-7","volume":"21","author":"SO Hasenleithner","year":"2022","unstructured":"Hasenleithner SO, Speicher MR. A clinician\u2019s handbook for using ctdna throughout the patient journey. Mol Cancer. 2022;21:81.","journal-title":"Mol Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07280-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07280-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07280-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:51:52Z","timestamp":1757159512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07280-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7280"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07280-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Medical University of Vienna (ID: 1649\/2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No potential conflicts of interest relevant to this article exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}